Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-OncologyTM through the development of novel treatments for solid-tumor cancers. IP-001, the first asset from the company’s intellectual property platform, has the potential to transform a routine tumor ablation into a systemically active cancer immunotherapy. Immunophotonics is also exploring the use of its technology platform to help prevent and combat contractions of infectious diseases.  Immunophotonics is headquartered in St. Louis, Missouri, with subsidiaries in Bern, Switzerland, and Tianjin, China.

Our issued and pending patents, which are wholly owned by Immunophotonics, support and protect a strong pipeline of convenient, off-the-shelf therapies that are developed to treat patients with cancer. The composition of matter surrounding IP-001 has been patented in over 40 countries representing key markets in oncology across the globe.

Team

Lu Alleruzzo, MBA

CEO, CO-FOUNDER, & BOARD MEMBER
Mr. Alleruzzo, a co-founder of Immunophotonics, is a BioEngineer with an MBA. His background includes basic research experience before transitioning into business roles in the healthcare industry. Additional board service roles include the NIH Midwest Biomedical Accelerator Consortium, Missouri Biotechnology Association and American Cancer Society. 10+ years life sciences industry experience.

Tomas Hode, Ph.D.

CHIEF INNOVATION OFFICER, PRESIDENT, CO-FOUNDER, & BOARD MEMBER
Dr. Hode is a co-founder of Immunophotonics and has 30 years’ experience in life science, both in industry and academia. He received his PhD from Stockholm University, Sweden, focusing on analytical development, did a post-doc in the USA, and subsequently returned to industry with Immunophotonics.

Edwina Baskin-Bey, M.D.

CHIEF MEDICAL OFFICER
Dr. Baskin-Bey is an international oncology biopharmaceutical veteran with more than 20-years’ experience in academia and industry. Dr. Baskin-Bey received a bachelor’s degree in Chemistry from Hunter College, NY, NY, and a medical degree from Mount Sinai/NYU School of Medicine, NY, NY.

David W. Anderson, Ph.D.

CHIEF SCIENTIFIC OFFICER
Dr. Anderson, Ph.D. (Immunology and Medical Microbiology) has deep expertise in target-based drug discovery/development and personalized molecular diagnostics in inflammation and oncology. He built and managed innovative drug discovery and development companies acquired by Celgene Corporation, Cypress Bioscience, Roche, and Nalo Therapeutics (Samsara BioCapital).

Diane M. Beatty, Ph.D.

VP OF REGULATORY & CLINICAL AFFAIRS
Dr. Beatty holds a Ph.D. in Chemistry/ Biochemistry from the University of Missouri - Kansas City. She has nearly 25 years of experience in the formulation and execution of scientific and regulatory strategies for drug, biologic, and device development programs. Dr. Beatty has extensive experience in leading development teams from discovery to post-approval.

Siu Kit “Samuel” Lam, Ph.D.

SENIOR VP OF SCIENCE AND RESEARCH
Dr. Lam received his Bachelor of Science degree in Molecular and Cellular Biology from John Hopkins University and his Ph.D. in Immunology from Washington University. He also acquired a master’s degree in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University. His primary role at Immunophotonics is to oversee the research and development of the company’s assets..

Joseph Raker, Ph.D.

SENIOR VP OF CMC
Dr. Raker has over 30 publications and patents and holds a B.S. in Chemistry from Utica College of Syracuse University and a Ph.D. in Organic Chemistry from The Pennsylvania State University. Dr. Raker joined Immunophotonics in 2014 and oversees all CMC operations for the company.

Theresa Visarius, Ph.D.

VP BUSINESS DEVELOPMENT
MANAGING DIRECTOR - IPS BIOPHARMA AG (Swiss Subsidiary)



Dr. Visarius is the Vice President of Business Development at Immunophotonics and Managing Director of the Swiss subsidiary IPS Biopharma AG. She joined the company in 2015 after 8 years as an entrepreneur where she worked with global leaders in health care as well as start-ups to facilitate market access of innovative medical technologies.

Alexander M. Hurst, J.D./M.B.A.

GENERAL COUNSEL & DIRECTOR OF OPERATIONS
Mr. Hurst joined Immunophotonics in 2019 after working in private practice, where he provided outside general counsel services to numerous startups and small businesses. At Immunophotonics, he uses his dual background as a J.D./M.B.A. to oversee the company’s legal matters, operations management, and IP portfolio.

Board of Directors

Bobby W. Sandage, Jr., Ph.D.

CHAIRMAN
Dr. Sandage has over 35 years of experience in the pharmaceutical industry in drug development and senior management and currently Managing Director of the Riney Family Foundation and General Partner in Cultivation Capital Life Sciences Fund II.

Jonathan Knowles, Ph.D.

DIRECTOR
Dr. Knowles has a distinguished career in the pharmaceutical industry as well as academia. He was the founding Chairman of the Board and central to the establishment of the Innovative Medicines Initiative.

Charlie Bolten

DIRECTOR
Mr. Bolten is a Senior Vice President of BioGenerator, a seed stage investment group. He has extensive R&D experience having 10 years’ experience working at large pharmaceutical companies.

Miguel Zubizarreta

DIRECTOR
Mr. Zubizarreta served as Chief Technology Officer and Executive Vice President of Hyland Software Inc. He has a bachelor’s degree in computer engineering from Case Western Reserve University. Mr. Zubizarreta is a recognized authority in ECM and has been a speaker or panel member at many different annual conferences for the last decade.

Wei R. Chen, Ph.D.

INVENTOR
Dr. Chen is a co-inventor of inCVAX (IP-001) and a co-founder of Immunophotonics, Inc. His research focuses on laser medicine, with a special emphasis on ablation-based immunotherapy for metastatic cancers.

Scientific Advisory Board

Daniel Von Hoff, M.D., F.A.C.P.

CLINICAL DEVELOPMENT
Dr. Von Hoff has conducted clinical trials on more than 200 antineoplastic and biologic agents. He currently serves as Distinguished Professor and Executive Vice President of the Translational Genomics Research Institute.

Richard Levenson, M.D.

CLINICAL DEVELOPMENT
Dr. Levenson is currently a Professor at the Pathology Department at UC Davis. He received his undergraduate degree at Harvard College, his medical degree at the University of Michigan and his pathology training at Washington University, St. Louis.

Mark Naylor, MD

CLINICAL DEVELOPMENT
Dr. Naylor received his medical degree from Texas Tech University School of Medicine and his specialty certificate in internal medicine from the University of Alabama. He completed his scientific fellowship in tumor biology at the MD Anderson Cancer Center.

Richard A. Stark

BUSINESS ADVISOR
Mr. Stark has over 25 years’ experience in high-level positions within the medical device sector, with a focus on ablation devices. He currently serves as a board member and company president of Sanarus Technologies, Inc.

Rolf K. Hultsch, M.D.

CLINICAL DEVELOPMENT - INTERVENTIONAL RADIOLOGY
Dr. Hultsch is an interventional radiologist in practice for 16 years at Scottsdale Medical Imaging, Ltd., in Scottsdale, Arizona. His particular area of interest is interventional oncology with procedures including percutaneous ablation, chemoembolization, and radioembolization.

Robert C. G. Martin, II, M.D. Ph.D.

CLINICAL DEVELOPMENT
Dr. Martin has completed over 15 prospective clinical trials and was principal investigator of 1 Humanitarian Device Exemption (HDE), 2 Investigation New Drugs (IND), and 3 Investigational Device Exemption (IDE) trials.

Jonathan Barnes, Ph.D.

CMC DEVELOPMENT
Dr. Barnes completed his B.S. and M.S. degrees in chemistry at the University of Kentucky. Dr. Barnes has expertise in biopolymers and polymer-based cancer therapies, and more broadly, polymer synthesis and characterization.

David Smoller, Ph.D.

BUSINESS ADVISOR
Dr. Smoller earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta. He is a General Partner at Cultivation Capital and previously served as the Chief Scientific Officer of Sigma-Aldrich Corporation.

Collaborators

Immunophotonics has collaborations with researchers at top universities across the globe.  Through these partnerships, many of which are federally funded, Immunophotonics is always making strides toward advancing the science behind the field of Interventional Immuno-Oncology and our understanding of the immune system at large.

USA: 🇺🇸

The University of Missouri (Mizzou) Columbia, Missouri, USA
The University of Missouri (Mizzou) Columbia, Missouri, USA
UC Davis University Davis, California, USA
UC Davis University Davis, California, USA
The University of Oklahoma Norman, Oklahoma, USA
The University of Oklahoma Norman, Oklahoma, USA
The University of Louisville Louisville, Kentucky, USA
The University of Louisville Louisville, Kentucky, USA
IQVIA, Inc. Durham, North Carolina, USA
IQVIA, Inc. Durham, North Carolina, USA

Switzerland: 🇨🇭

The Swiss Group of Clinical Cancer Research (SAKK) Bern, Switzerland
The Swiss Group of Clinical Cancer Research (SAKK) Bern, Switzerland
University of Zurich KSSG Zurich, Switzerland
University of Zurich KSSG Zurich, Switzerland
Kantonsspital St. Gallen St. Gallen, Switzerland
Kantonsspital St. Gallen St. Gallen, Switzerland
Kantonsspital Graubünden Chur, Switzerland Chur 7000
Kantonsspital Graubünden Chur, Switzerland Chur 7000

China: 🇨🇳

Shenzhen University  Shenzhen, Guangdong Province, China
Shenzhen University Shenzhen, Guangdong Province, China
Huazhong University of Science and Technology  Wuhan, Hubei, China
Huazhong University of Science and Technology Wuhan, Hubei, China
Shanghai Skin Diseases Hospital Tongji University School of Medicine Shanghai, China
Shanghai Skin Diseases Hospital Tongji University School of Medicine Shanghai, China
Hainan University  Haikou, Hainan, China
Hainan University Haikou, Hainan, China
South China Normal University  Guangzhou, China
South China Normal University Guangzhou, China

Canada: 🇨🇦

British Columbia Cancer Agency (BCCA)  Vancouver, British Columbia, Canada
British Columbia Cancer Agency (BCCA) Vancouver, British Columbia, Canada

Taiwan: 🇹🇼

University of TaipeiTaipei City, Taipei, Taiwan
University of TaipeiTaipei City, Taipei, Taiwan

Germany: 🇩🇪

The University of Münster  Münster, Germany
The University of Münster Münster, Germany